Informationen:
Fehler:
ID
18552
Beschreibung
Phase II Iressa Versus Vinorelbine (INVITE); ODM derived from: https://clinicaltrials.gov/show/NCT00256711
Link
https://clinicaltrials.gov/show/NCT00256711
Stichworte
Versionen (1)
- 10.11.16 10.11.16 -
Hochgeladen am
10. November 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Non-Small-Cell Lung Carcinoma NCT00256711
Eligibility Non-Small-Cell Lung Carcinoma NCT00256711
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Non-Small-Cell Lung Carcinoma NCT00256711
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Non-Small Cell Lung Carcinoma | Tumor tissue Paraffin Embedded Providing
Item
histologically confirmed nsclc and willing to provide paraffin embedded tumour tissue
boolean
C0007131 (UMLS CUI [1])
C0475358 (UMLS CUI [2,1])
C1519524 (UMLS CUI [2,2])
C1999230 (UMLS CUI [2,3])
C0475358 (UMLS CUI [2,1])
C1519524 (UMLS CUI [2,2])
C1999230 (UMLS CUI [2,3])
Non-Small Cell Lung Carcinoma Advanced Locally | Non-small cell lung cancer metastatic | TNM clinical staging | Disease Amenable Curative Surgery | Disease Amenable Chemoradiotherapy naive | Life Expectancy
Item
nsclc - locally advanced (stage iiib) or metastatic (stage iv) disease, not amenable to curative surgery or radiotherapy chemonaïve, life expectancy of 12 weeks
boolean
C0007131 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C0278987 (UMLS CUI [2])
C3258246 (UMLS CUI [3])
C0012634 (UMLS CUI [4,1])
C3900053 (UMLS CUI [4,2])
C1511562 (UMLS CUI [4,3])
C0012634 (UMLS CUI [5,1])
C3900053 (UMLS CUI [5,2])
C0436307 (UMLS CUI [5,3])
C0919936 (UMLS CUI [5,4])
C0023671 (UMLS CUI [6])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C0278987 (UMLS CUI [2])
C3258246 (UMLS CUI [3])
C0012634 (UMLS CUI [4,1])
C3900053 (UMLS CUI [4,2])
C1511562 (UMLS CUI [4,3])
C0012634 (UMLS CUI [5,1])
C3900053 (UMLS CUI [5,2])
C0436307 (UMLS CUI [5,3])
C0919936 (UMLS CUI [5,4])
C0023671 (UMLS CUI [6])
WHO performance status scale
Item
who performance status <= 2
boolean
C1298650 (UMLS CUI [1])
CNS metastases
Item
newly diagnosed cns metastases
boolean
C0686377 (UMLS CUI [1])
Therapeutic radiology procedure Complete | Toxic effect persistent Therapeutic radiology procedure Related
Item
less than 4 weeks since completion of radiotherapy or persistence of any radiotherapy related toxicity.
boolean
C1522449 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C0205322 (UMLS CUI [2,2])
C1522449 (UMLS CUI [2,3])
C0439849 (UMLS CUI [2,4])
C0205197 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C0205322 (UMLS CUI [2,2])
C1522449 (UMLS CUI [2,3])
C0439849 (UMLS CUI [2,4])
Hypersensitivity ZD1839 | Hypersensitivity vinorelbine Intravenous
Item
hypersensitivity to zd1839 or intravenous vinorelbine
boolean
C0020517 (UMLS CUI [1,1])
C0879396 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0078257 (UMLS CUI [2,2])
C1522726 (UMLS CUI [2,3])
C0879396 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0078257 (UMLS CUI [2,2])
C1522726 (UMLS CUI [2,3])
Epidermal growth factor receptor inhibitor
Item
prior treatment with egfr inhibitors
boolean
C1443775 (UMLS CUI [1])
Malignant Neoplasms
Item
other co-existing malignancies
boolean
C0006826 (UMLS CUI [1])
Alanine aminotransferase measurement | Aspartate aminotransferase measurement
Item
alt/ast >2.5 x ulrr
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201899 (UMLS CUI [2])
Absolute neutrophil count | Platelet Count measurement
Item
anc < 2.0 x 10^9/l or platelets < 100 x 10^9/l
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0032181 (UMLS CUI [2])